The effects of leukotriene receptor antagonist montelukast on histological, radiological and densitometric parameters of fracture healing

被引:0
作者
Cakici, Husamettin [1 ]
Hapa, Onur [3 ]
Gideroglu, Kaan [4 ]
Ozturan, Kutay [1 ]
Guven, Melih [1 ]
Yuksel, Halil Yalcin [5 ]
Yilmaz, Fahri [2 ]
机构
[1] Abant Izzet Baysal Univ, Tip Fak, Ortopedi & Travmatol Anabilim Dali, TR-14280 Golkoy, Bolu, Turkey
[2] Abant Izzet Baysal Univ, Tip Fak, Dept Pathol, TR-14280 Golkoy, Bolu, Turkey
[3] Mustafa Kemal Univ, Fac Med, Dept Orthoped & Traumatol, Antakya, Turkey
[4] Dr Lutfi Kirdar Training & Res Hosp, Dept Plast & Reconstruct Surg, Istanbul, Turkey
[5] Ankara Numune Training & Res Hosp, Dept Orthoped & Traumatol 3, Ankara, Turkey
来源
EKLEM HASTALIKLARI VE CERRAHISI-JOINT DISEASES AND RELATED SURGERY | 2011年 / 22卷 / 01期
关键词
Experimental study; fracture healing; leukotriene-receptor antagonist; montelukast; ISCHEMIA/REPERFUSION INJURY; RATS; INDOMETHACIN; CELECOXIB; PROTECTS; REPAIR;
D O I
暂无
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Objectives: In this study we evaluated the effects of montelukast, a leukotriene-receptor antagonist, on fracture healing, and investigated the hypothesis that enhanced fracture healing would be observed with montelukast in a rat tibia fracture model. Materials and methods: Sixty adult (6 months old) female Wistar albino rats (mean weight 220 g, range 210-270 g) were randomly divided into two groups: a montelukast group (n=30) and a control group (n=30). Closed tibia fractures were created and fixed by intramedullary Kirschner wire. The rats were sacrificed three and six weeks after the fractures. Radiological and histological evaluations were performed, and bone mineral density was measured. Results: Three rats died in the montelukast group, whereas only one died in the control group during the study. Initial weight and weight gain at the 3(rd) and 6(th) weeks were not significantly different between the groups (p>0.05). Bone mineral densities in the control and study groups were 0.13 +/- 0.009 gr/cm(2), and 0.13 +/- 0.01 gr/cm(2) at week three and 0.16 +/- 0.02 gr/cm(2), and 0.13 +/- 0.01 gr/cm(2) at week six, respectively. Histopathological scores in the control and study groups were 3.42 +/- 0.6, and 3.0 +/- 0.0 at week three and 3.5 +/- 0.5, and 3.4 +/- 0.8 at week six, respectively. Radiological scores in the control and study groups were 1.19 +/- 0.6, and 1.0 +/- 0.6 at week three and 3.0 +/- 0.8, and 2.9 +/- 0.9 at week six, respectively. There were no significant differences between the two groups in any parameters evaluated at either time interval (p>0.05). Conclusion: Our study failed to show a possible positive effect of leukotriene receptor inhibition on fracture healing at the 3(rd) and 6(th) postoperative weeks.
引用
收藏
页码:43 / 47
页数:5
相关论文
共 50 条
  • [31] PHARMACOLOGY OF MONTELUKAST SODIUM (SINGULAIR(TM)), A POTENT AND SELECTIVE LEUKOTRIENE D-4 RECEPTOR ANTAGONIST
    JONES, TR
    LABELLE, M
    BELLEY, M
    CHAMPION, E
    CHARETTE, L
    EVANS, J
    FORDHUTCHINSON, AW
    GAUTHIER, JY
    LORD, A
    MASSON, P
    MCAULIFFE, M
    MCFARLANE, CS
    METTERS, KM
    PICKETT, C
    PIECHUTA, H
    ROCHETTE, C
    RODGER, IW
    SAWYER, N
    YOUNG, RN
    ZAMBONI, R
    ABRAHAM, WM
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1995, 73 (02) : 191 - 201
  • [32] Radiological Evaluation of the effects of varied doses of Celecoxib on fracture healing in dogs
    Uwagie-Ero, Edwin Aihanuwa
    Kene, Rapheal Chukwujekwu
    VETERINARY WORLD, 2011, 4 (02) : 75 - 76
  • [33] Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist
    Tugtepe, Halil
    Sener, Goksel
    Cetinel, Sule
    Velioglu-Ogunc, Ayliz
    Yegen, Berrak C.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 557 (01) : 69 - 75
  • [34] Effect of Montelukast, a Cysteinyl Leukotriene Receptor-1 Antagonist, on a Rat Model of Acute Bacterial Sinonasal Inflammation
    Kaya, Zulkuf
    Yayla, Muhammed
    Cinar, Irfan
    Celebi, Demet
    Toktay, Erdem
    Bayraktutan, Zafer
    Bilici, Dilek
    AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2019, 33 (05) : 559 - 566
  • [35] Montelukast, A Selective Cysteinyl Leukotriene Receptor 1 Antagonist, Reduces Cerulein-Induced Pancreatic Injury in Rats
    Ozkan, Erkan
    Akyuz, Cebrail
    Sehirli, Ahmet Ozer
    Topaloglu, Umit
    Ercan, Feriha
    Sener, Goksel
    PANCREAS, 2010, 39 (07) : 1041 - 1046
  • [36] Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier
    Zhou, Li
    Sun, Xiaomin
    Shi, Yong
    Liu, Junpeng
    Luan, Guohui
    Yang, Yanwen
    INFLAMMOPHARMACOLOGY, 2019, 27 (05) : 933 - 940
  • [37] Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats
    Mohamed, Mervat Z.
    Zenhom, Nagwa M.
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2020, 149
  • [38] Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged ≥ 6 years
    Storms, W
    Michele, TM
    Knorr, B
    Noonan, G
    Shapiro, G
    Zhang, J
    Shingo, S
    Reiss, TF
    CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (01) : 77 - 87
  • [39] Treatment of Allergic Rhinitis in Infants and ChildrenEfficacy and Safety of Second-Generation Antihistamines and the Leukotriene Receptor Antagonist Montelukast
    Hanna Phan
    Matthew L. Moeller
    Milap C. Nahata
    Drugs, 2009, 69 : 2541 - 2576
  • [40] Non-obvious effects of montelukast - leukotriene receptor blocker: frigoprotective and anticonvulsant properties
    Shtrygol, S. Yu
    Kapelka, I. G.
    Mishchenko, M., V
    Mishchenko, O. Ya
    MEDICNI PERSPEKTIVI, 2021, 26 (02): : 19 - 25